Arrowhead Pharma reports FY2023 net loss of $205M, pipeline advances

ARROWHEAD PHARMACEUTICALS, INC.

2023-FY EPS reported -$1.92 revenue$240,735,000

Revenue $240.7M vs $243.2M YoY; net loss $205.3M (EPS -$1.92) vs $176.1M (-$1.67).
Cash and investments $403.6M, down from $482.3M; R&D spend up 19% to $353M.
Plozasiran (APOC3) showed up to 90% APOC3 reduction in Phase 2 severe hypertriglyceridemia.
Completed GLP tox for pulmonary candidates ARO-RAGE and ARO-MMP7; planning Phase 2.
GSK acquired full rights to JNJ-3989 (ARO-HBV) from Janssen; Arrowhead retains no further obligations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

ARROWHEAD PHARMACEUTICALS, INC. reported fiscal year ended September 30, 2023 results: revenue $ 240,735, net income $ (205,275), EPS $ (1.92).

Period: fiscal year ended September 30, 2023
Revenue: $ 240,735
Net income: $ (205,275)
EPS: $ (1.92)
Result: reported results

Exact text from the filing

PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended September 30, OPERATING SUMMARY 2023 2022 Revenue $ 240,735 $ 243,231 Operating Expenses: Research and development 353,188 297,307 General and administrative expenses 92,549 124,431 Total Operating Expenses 445,737 421,738 Operating loss

View on SEC.gov

Browse all earnings releases →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-040222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.